REGENXBIO (NASDAQ:RGNX) Issues Quarterly Earnings Results, Beats Expectations By $0.35 EPS

REGENXBIO (NASDAQ:RGNX) issued its earnings results on Thursday. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.35, FiscalAI reports. The business had revenue of $108.02 million during the quarter, compared to the consensus estimate of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%.

Here are the key takeaways from REGENXBIO’s conference call:

• REGENXBIO ended the quarter with more than $310 million pro forma, following a $100 million AbbVie milestone and a $108 million follow-on offering. Management expects this to fund operations into Q4 2027, including the anticipated RGX-202 PDUFA date.
• RGX-202 enrollment and dosing in the confirmatory Duchenne muscular dystrophy study were completed ahead of schedule, with more than 60 patients across pivotal and confirmatory studies. The company plans to submit the first BLA module in Q3 2026 and initiate the global AFFINITY RISE trial in the first half of 2027.
• The FDA agreed that RGX-121’s existing data are sufficient for accelerated-approval review and said no additional studies, including a randomized controlled trial, are required for BLA resubmission. REGENXBIO plans to resubmit the application in Q3 2026 with longer-term efficacy, safety, imaging, and neurocognitive data.
• REGENXBIO and AbbVie began the Phase IIb/III NAAVIGATE study of sura-vec in diabetic retinopathy, triggering the $100 million milestone payment. The partners expect fourth-quarter top-line results from the ATMOSPHERE and ASCENT wet AMD studies, while longer-term follow-up showed durable effects and favorable safety through five years in wet AMD and 2.5 years in diabetic retinopathy.
• The company acknowledged that its U.S. patent covering Zolgensma has expired, although royalties will continue in roughly 20 countries outside the United States. Management highlighted Evrysdi coverage and potential future royalties from Itvisma as offsets, but did not provide specific royalty-rate guidance.

REGENXBIO Price Performance

Shares of NASDAQ RGNX traded down $0.56 during trading on Friday, hitting $10.72. The stock had a trading volume of 1,386,330 shares, compared to its average volume of 1,837,961. The firm has a fifty day moving average of $10.02 and a two-hundred day moving average of $9.43. The company has a market capitalization of $554.22 million, a PE ratio of -2.83 and a beta of 0.94. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on RGNX shares. Bank of America cut their price objective on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Zacks Research lowered REGENXBIO from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wall Street Zen upgraded shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Saturday. Finally, Leerink Partners upped their price objective on shares of REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Insider Buying and Selling at REGENXBIO

In related news, insider Steve Pakola sold 36,725 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total transaction of $472,283.50. Following the transaction, the insider directly owned 213,009 shares in the company, valued at approximately $2,739,295.74. The trade was a 14.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 73,803 shares of company stock worth $886,937 over the last 90 days. 14.22% of the stock is owned by company insiders.

Hedge Funds Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its holdings in shares of REGENXBIO by 5.4% in the fourth quarter. Invesco Ltd. now owns 157,903 shares of the biotechnology company’s stock valued at $2,274,000 after acquiring an additional 8,023 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in REGENXBIO by 21.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 24,140 shares of the biotechnology company’s stock worth $348,000 after acquiring an additional 4,224 shares during the period. Vestal Point Capital LP purchased a new position in REGENXBIO in the fourth quarter worth $490,000. Virtus Investment Advisers LLC boosted its position in REGENXBIO by 71.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 19,181 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 8,026 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in REGENXBIO in the 4th quarter valued at $350,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Key Headlines Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Strong Q2 results: REGENXBIO reported earnings of $0.43 per share, well above analyst estimates of $0.08–$0.12, while revenue of $108.0 million exceeded the $97.6 million consensus estimate. The result compares with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Key pipeline milestones remain on track: The company said its RGX-202 gene therapy filing for Duchenne muscular dystrophy is expected to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. RGX-121 for Hunter syndrome is also targeted for resubmission in Q3 2026, while pivotal wet age-related macular degeneration data are expected in Q4 2026. REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Improved financial flexibility: More than $200 million of new capital raised in July increased pro forma cash, cash equivalents and marketable securities to over $310 million and extended the cash runway into the fourth quarter of 2027. This reduces near-term financing pressure as the company advances its programs. REGENXBIO Outlines Cash Runway
• Neutral Sentiment: Barclays maintained an Equal Weight rating and set a $12 price target, implying potential upside from recent trading levels but signaling a balanced view rather than a strong bullish recommendation. Barclays Rating Update
• Negative Sentiment: Profitability remains weak: Despite the quarterly beat, REGENXBIO continues to report a deeply negative net margin and return on equity, and analysts expect a full-year loss. Investors may therefore view the earnings improvement as less durable if it depends on licensing or other non-recurring revenue.
• Negative Sentiment: Material execution risk remains: The stock’s valuation and future upside depend heavily on successful regulatory filings, clinical data and eventual commercialization of its gene-therapy programs. Delays, safety concerns or disappointing trial results could pressure RGNX.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.